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Abstract
Objectives Across diagnosis groups, transition of adolescents and young adults from children’s hospitals to adult care associates
with decreased treatment adherence and suboptimal treatment results. Our aim was to compare the health-related quality of life
(HRQoL) and disease activity of juvenile idiopathic arthritis (JIA) patients after the transfer of care to the adult clinic and adult
patients in the same outpatient clinic.
Methods All consecutive JIA patients aged 16 to 20 years who visited the transition clinic between September 2016 and August
2017 and all consecutive adult onset arthritis patients between December 2016 and August 2017 in the rheumatology outpatient
clinic of Helsinki University Hospital were evaluated. HRQoL was measured by a generic instrument, 15D.
Results A total of 291 patients, 130 JIA, and 161 adults were identified with respective median disease durations of 6.5 and
4.0 years. Adults had lower HRQoL measured by 15D (median 0.90 vs. 0.96, P < 0.001) and higher Disease Activity Score 28
(DAS28) than JIA patients (median 2.4 vs. 1.6, P < 0.001). Adults smoked more frequently than JIA patients (22% vs. 7%,
P < 0.001). In multiple regression, female gender, smoking, disease activity, and obesity were associated with poorer HRQoL.
Smoking adults had more active disease (DAS28 median 3.1 vs. 2.1, P = 0.031) and lower HRQoL (15D median 0.86 vs. 0.93,
P < 0.001) than non-smoking adults.
Conclusions Transition phase JIA patients had acceptable HRQoL and lower disease activity than patients with adult onset
rheumatic diseases with similar disease duration. Smoking was associated with more active disease and lower HRQoL.
Keywords Disease-modifying antirheumatic drugs . Juvenile idiophatic arthritis . Rheumatoid arthritis . Smoking .
Transition of care
Introduction
Juvenile idiopathic arthritis (JIA) is a group of arthritides that
emerge before the age of 16 [1]. The incidence of JIA in the
Nordic countries is 15–19.5/100,000 [2]. The course of disease
varies from self-limiting monoarthritis to chronic and destructive
forms of polyarthritis [3] which have influences that carry over
into adulthood [4]. Up to 50% of JIA patients were not in remis-
sion 8 years after diagnosis in a Nordic population-based study
[5], and a majority of patients were not in remission when
followed up as young adults [6]. Radiological joint damage
may be as common as in adult onset rheumatoid arthritis [7].
The health-related quality of life (HRQoL) of adult patients
with various rheumatic diseases is significantly lower than that of
the general population [8]. Similar findings are true for JIA pa-
tients in adulthood [9–11]. Among adolescents, JIA has a greater
effect on physical than mental HRQoLmeasures during the tran-
sition of care [12]. However, less is known about HRQoL and
disease activity of young JIA patients compared with other pa-
tients attending an adult rheumatology clinic.
Although the prognosis of JIA has improved in the past de-
cades [13], transition from pediatric care to an adult clinic is a
challenging time period for maintaining a good patient-doctor
relationship as well as continuity of treatments and satisfactory
disease control. Transition of care programs have been developed
to meet the special needs of adolescent patients [14–17], and
recommendations for the transition of care for young people with
JIA have recently been updated [18]. The transition phase (12–
24 years) is a critical period to avoid joint damage in adulthood.
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The transition process spans several years and begins with
preparation of the patient and family for the transfer of care
from pediatricians to adult specialists. Actual transfer of care
with close collaboration of specialists involved in patient care
finally leads to follow-up at the adult clinic [14]. During the
third and final phase of transition in the adult clinic, patients
still require special attention from service providers due to the
patients’ young age, gradually increasing autonomy and great
differences in maturation between individuals.
The aim of this study was to compare the HRQoL and
disease activity of young JIA patients whose care has been
transferred to an adult rheumatology clinic and adult patients
with similar disease duration. We hypothesized that due to the
known challenges during transition of care, young JIA pa-
tients would have lower HRQoL and worse disease activity
outcomes compared to adult onset rheumatic disease patients
with similar disease duration.
Material and methods
Patient cohorts
Practically all JIA patients who require follow-up after treat-
ment by specialists in pediatric rheumatology in Southern
Finland are referred to the Helsinki University Hospital
(HUH) Rheumatology outpatient transition clinic (back-
ground population 1.6 million). The transfer of rheumatology
patients from pediatric to adult care occurs based on individual
assessment at the age of 16–18 years. The transition process of
rheumatology patients in the HUH area has been described
previously [19]. Since public health care in Finland is based
on universal health coverage, insurance type is irrelevant.
Using the electronic patient registry of our hospital, we
identified two patient cohorts which included all consecutive
JIA patients aged 16 to 20 years (ICD-10 codesM08.0–M08.9
and M09.0*L40.5) who visited the HUH Rheumatology out-
patient transition clinic between September 2016 and August
2017 and all consecutive adult onset arthritis patients aged 18
to 65 years (ICD-10 codes M05–M06, M13, M45–M46, and
M07.3*L40.5) between December 2016 and August 2017 in
the respective outpatient clinic. Ankylosing spondylitis (AS)
(ICD-10 code M45) and axial spondyloarthritis (ICD-10
code s M46 .1–M46 .9 ) we r e comb ined in to the
spondyloarthritis (SpA) group. All study participants had a
pre-established diagnosis and treatment regimen, and patients
with other potentially disabling diseases were excluded.
Clinical data
We conducted a meticulous review of the electronic patient
records and collected data on previous and ongoing medica-
tions, smoking status, and body mass index (BMI). Disease
outcome was evaluated using the Health Assessment
Questionnaire Disability Index (HAQ-DI) [20] and Disease
Activity Scores 28 (DAS28) [21, 22]. The DAS-C-reactive
protein (DAS-CRP) is a modification of the DAS28. The
original DAS28 includes the erythrocyte sedimentation rate
(ESR) value, while the DAS-CRP uses the serum CRP con-
centration instead. In the following, DAS28 refers to DAS28-
CRP which was the primary outcome measure for patients
with peripheral disease. Bath AS Disease Activity Index
(BASDAI) [23] was used in patients with enthesitis-related
arthritis (ERA) (ICD-10 code M08.1) and SpA.
The HAQ-DI assesses the patient’s ability to perform 20
activities of daily living on a four-point Likert scale (from
Bwithout any difficulty^ to Bnot able to do^; respective scores
ranging from 0 to 3). These activities are divided into eight
categories; the category score is the highest score of any ac-
tivity within the category. The total HAQ-DI score is the mean
of the category scores. Pain was measured on a 10-cm visual
analog scale (VAS) [24].
HRQoL was measured using the 15D (http://www.15d-
instrument.net/15d/), a generic instrument which can be used
as a profile and a single score measurement [25]. The 15D
questionnaire consists of 15 dimensions: mobility, vision,
hearing, breathing, sleeping, eating, speech, excretion, usual
activities, mental function, discomfort and symptoms,
depression, distress, vitality, and sexual activity. For each
dimension, the patient chooses one of the five levels that
best describes her/his state of health at the moment. The opti-
mal total score equals 1.0, and the minimum important differ-
ence in 15D scores is 0.015.
Ethics
Retrospective data were used, and patients were not contacted
for this study. Thus, ethics approval was not required for this
study at our institution.
Statistical methods
Data are presented as means (± standard deviation, SD) for
continuous variables, or in case of skewed distribution, medi-
an (with range). Percentages are reported for categorical var-
iables. t tests were used to compare normally distributed con-
tinuous variables. When distribution was skewed, the Mann-
Whitney U test and Spearman correlation were used. Multiple
regression was conducted to examine the differences in
HRQoL in the two patient cohorts while accounting for sex,
smoking status, and remission as categorical variables and
BMI and disease duration as continuous variables. A P value
< 0.05 was considered statistically significant. Data analyses
were performed using IBM SPSS Statistics 22 (IBM, Somers,
NY).
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Results
A total of 291 patients were identified. The two groups were
similar with regard to gender distribution and disease duration,
but JIA patients were leaner and less frequently smokers
(Table 1). Smoking was fairly frequent in the different adult
diagnosis groups: 23% of seronegative or seropositive arthritis
patients, 25% of PsA patients, and 22% of SpA patients were
smokers. The distribution of diagnoses is shown in Fig. 1.
Patients with adult onset arthritides were more often seropos-
itive than were JIA patients. Psoriatic arthritis (PsA) was the
least common diagnosis in both groups.
Disease activity
According to the DAS28 remission criteria [21], 86% of JIA
patients and 53% of adult patients were in remission (DAS28
< 2.6). Disease activity was low (DAS28 2.6–3.2) in 10% of
JIA and 22% of adult patients, and high (DAS28 > 3.2) in 4%
of JIA and 25% of adult patients, respectively. Other disease
activity parameters are shown in Table 1. Disease activity was
similar between females and males in both patient groups. All
JIA patients reported lower levels of pain on the VAS than did
adults. Median pain VAS was higher among JIA females than
among JIA males (13.5, range 0–76 vs. 8.5, range 0–50; P =
0.029). BASDAI was similar between ERA and SpA patients.
Non-ERA JIA patients had lower disease activity measured by
DAS28 and better functional status measured by HAQ-DI
than non-SpA adults. Adult smokers had higher pain VAS,
increased disease activity measured by DAS28 or BASDAI,
and poorer functional status measured by HAQ-DI than non-
smoking adults (Table 2). We found no significant differences
in disease activity measures among smoking and non-
smoking JIA patients, but only nine JIA patients (7%) were
smokers.
Quality of life
JIA patients had significantly higher median 15D scores than
adults (Table 1). Of the 15 dimensions covered by 15D, JIA
patients scored significantly higher than adults in 12 dimen-
sions: mobility, vision, hearing, breathing, sleeping, excretion,
usual activities, mental function, discomfort and symptoms,
depression, vitality, and sexual activity (Fig. 2). JIA females
scored slightly lower on the 15D (0.93 ± 0.05 vs. 0.96 ± 0.06,
P = 0.021, respectively) than did JIA males. Adult smokers
had significantly lower 15D score than non-smoking adults
(Table 2). These differences were evident in nine dimensions:
mobility, eating, usual activities, mental function, discomfort
and symptoms, depression, distress, vitality, and sexual activ-
ity (Fig. 3). Adult smokers’ 15D scores were also inferior to
smoking JIA patients’ scores. Smoking JIA patients had lower
15D scores on breathing (0.87 ± 0.20 vs. 0.97 ± 0.08, P =
0.014, respectively) and sexual function (0.97 ± 0.10 vs. 1.0
± 0.03, P = 0.017, respectively) than non-smoking JIA pa-
tients. Overweight (BMI > 25) adults had lower HRQoL than
normal weight adults (15D score 0.86 ± 0.11 vs. 0.89 ± 0.09,
P = 0.028, respectively). HRQoL was similar in overweight
and normal weight JIA patients. In multiple regression, female
gender, smoking, active disease, and increasing BMI were
significantly associated with lower HRQoL (Table 3).
Table 1 Clinical characteristics and disease activity parameters of
juvenile idiopathic arthritis (JIA) patients and adult onset arthritides
JIA, n = 130 Adults, n = 161
Females (n (%)) 92 (71) 114 (71)
Age (years) 18 (16–20) 39 (18–65)*
Duration of the disease (years) 7 (1–18) 4 (0–38)
BMI (kg/m2) 22.2 ± 3.8 26.8 ± 5.8*
CRP (mg/dl) 1 (1–40) 1 (1–55)
Pain VAS (mm) 12 (0–76) 25 (0–99)*
DAS28a 1.6 (1.4–5.3) 2.4 (1.4–5.6)*
HAQ-DIa 0 (0–1.5) 0.25 (0–2.5)*
BASDAIb 1.0 (0–5.7) 1.7 (0–8.9)
15D 0.96 (0.77–1.0) 0.90 (0.53–1.0)*
Smoking (n (%)) 9 (7) 36 (22)*
BMI bodymass index,CRPC-reactive protein, VAS visual analogic scale,
DAS28 Disease Activity Score 28, HAQ-DI Health Assessment
Questionnaire Disability Index, BASDAI Bath Ankylosing Spondylitis
Disease Activity Index
*P < 0.01 for difference between groups
a DAS28 and HAQ-DI available for JIA excluding enthesitis-related ar-
thritis (ERA), n = 107; adults excluding spondyloarthritides (SpA), n =
124
b BASDAI available for ERA, n = 23; SpA adults, n = 40
A JIA B Adults
Fig. 1 Distribution of diagnoses of A juvenile idiopathic arthritis (JIA)
and B adult onset arthritis patients. Seropositive arthritis 10% and 34%;
seronegative arthritis 70% and 30%; psoriatic arthritis 3% and 12%;
enthesitis-related arthritis/spondyloarthritis 17% and 24%; JIA and adult
patients, respectively
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Medications
Synthetic disease modifying anti-rheumatic drugs
(sDMARDs) were used by 80% of JIA and 74% of adult
patients, but sDMARD combination therapy was more com-
mon in adults (30% vs. 12%, P < 0.001). Biological
DMARDs (bDMARDs) were commonly used in both groups
(JIA 40% and adults 35%), whereas 10% of patients in either
group used no DMARDs. Cortisone was infrequently used by
JIA (5%) and adult patients (10%). We found no significant
difference in HRQoL between patients using only sDMARDs
or sDMARD and bDMARD combination therapy (data not
shown). HRQoL was also similar between patients with or
without methotrexate (data not shown).
Discussion
In the present study of consecutive rheumatology outpatient
clinic patients with pre-established diagnoses and treatment
regimens, transition phase JIA patients had acceptable
HRQoL and their disease activity and degree of disability
were lower than in patients with adult onset rheumatic dis-
eases with similar disease duration. In multiple regression in-



























Fig. 2 Health-related quality of life measured by 15D for juvenile
idiopathic arthritis (JIA) and adult patients (n = 130 and 161,
respectively). 1 mobility, 2 vision, 3 hearing, 4 breathing, 5 sleeping, 6
eating, 7 speech, 8 excretion, 9 usual activities, 10 mental function, 11
discomfort and symptoms, 12 depression, 13 distress, 14 vitality, 15



























Fig. 3 Health-related quality of life measured by 15D for non-smoking
and smoking adult onset arthritis patients (n = 126 and 35, respectively). 1
mobility, 2 vision, 3 hearing, 4 breathing, 5 sleeping, 6 eating, 7 speech, 8
excretion, 9 usual activities, 10 mental function, 11 discomfort and
symptoms, 12 depression, 13 distress, 14 vitality, 15 sexual activity.
*P < 0.05; **P < 0.01 between groups
Table 2 Clinical characteristics
and disease activity parameters of
non-smoking and smoking
juvenile idiopathic arthritis (JIA)
and adult onset arthritis patients
Non-smokers Smokers
JIA, n = 119 Adults, n = 126 JIA, n = 9 Adults, n = 35
Age (years) 18 (16–20) 39 (18–65) 19 (16–20) 41 (18–65)
BMI (kg/m2) 21.2 (16.4–40,6) 25.2 (17.9–43.1)## 23.7 (17.5–28.6) 27.2 (16.4–41.1)#
CRP (mg/dl) 1 (1–40) 1 (1–55) 1 (1–25) 3 (1–38)
Pain VAS (mm) 11 (0–76) 21.5 (0–90)## 26 (4–66) 41 (0–99)**
DAS28 1.6 (1.4–5.3) 2.1 (1.4–5.6)## 1.9 (1.4–4.2) 3.1 (1.4–5.5)*
HAQ-DI 0 (0–1.5) 0.13 (0–2.5)## 0 (0–6.0) 0.5 (0–2.1)**#
BASDAI 1.0 (0–5.7) 1.6 (0–6.2) 1.7 (1.3–2.9) 4.3 (0.9–8.9)*
15D 0.96 (0.80–1.0) 0.93 (0.57–1.0)## 0.92 (0.77–1.0) 0.86 (0.53–1.0)**#
Median (range)
BMI bodymass index,CRPC-reactive protein, VAS visual analogic scale,DAS28 disease activity score 28,HAQ-
DI health assessment questionnaire disability index, BASDAI bath ankylosing spondylitis disease activity index
*P < 0.05 from non-smokers; **P < 0.01 from non-smokers; #P < 0.05 from JIA; ##P < 0.01 from JIA
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disease activity, and increasing BMI were associated with
lower HRQoL.
In previous reports, JIA patients undergoing transition of
care [12], JIA patients in adulthood [9], and patients with adult
onset rheumatic diseases [8, 26] have had lower HRQoL than
the general population. To the best of our knowledge, this is
the first study to compare the HRQoL of young JIA patients
and patients with adult onset rheumatic diseases of similar
disease duration. Although JIA and adult onset rheumatic dis-
eases are partly different diseases [27], they share several
common features and can cause joint damage if treated inap-
propriately [7]. To achieve optimal treatment results, both JIA
and adult onset arthritides are treated with similar medications,
i.e., sDMARDs and bDMARDs [28, 29].
Although our study is limited by the retrospective data col-
lection, it also has several strengths. Our data presents two
comprehensive patient cohorts. The cohort of adult arthritides
was limited to working-age population to reduce age bias.
Furthermore, disease duration was similar between JIA pa-
tients and adults. Patients with other potentially disabling dis-
eases were excluded. We were, however, unable to assess the
impact of previous changes in medications on HRQoL or the
rates of possible complications, such as uveitis. Any changes in
vision were still captured by the 15D instrument, thus compen-
sating for this lack of data. We were also able to explore the
associations of smoking and obesity, two well-known risk fac-
tors for decreased HRQoL, in our patient cohorts.
Smoking was associated with poorer disease outcomes in
adults. Smoking habits differed significantly between JIA and
adult patients. According to the latest data [30], smoking is
more common among adults (12% of women and 13% of men
aged 20–84 years) than among adolescents (7% in age group
14–18 years) in Finland. In this study population, smoking
was as common among JIA patients as in the respective pop-
ulation in Finland, but smoking of adult patients exceeded the
population level. The proportion of smokers was similar in
different adult arthritis groups. It is possible that the reason
for the greater proportion of adult smokers in the present study
relates to smoking as an environmental risk factor for the
development of RA [31, 32]. Smoking is also a factor provok-
ing disease activity [33, 34] of arthritides. This may cause a
concentration effect of patients with more active and longer
standing diseases in the outpatient clinics. The proportion of
smokers in the present study is comparable to the earlier co-
horts of Swedish inflammatory arthritis patients [33, 34] and
the proportion of JIA smokers in the transition phase was
similar to our earlier transition cohort from 2015 [19].
Smoking has also been recognized as a cause for lower
HRQoL in general [35].
Obesity is associated with poorer disease outcomes in rheu-
matoid arthritis [36]. Adult patients were more often over-
weight than JIA patients in the present study. The proportion
of overweight (BMI > 25) patients was similar to the general
population in Finland [37]. Overweight/obese patients had
lower HRQoL than normal weight patients, but disease activ-
ity was similar in body weight groups.
Despite similar disease duration among JIA and adult
patients in this study, JIA patients had better disease outcomes
than patients with adult arthritides. The proportion of
bDMARDs was similar in both groups, whereas adults
were more often treated with a combination of sDMARDs.
Combination therapies with sDMARDs are commonly used for
treating adult rheumatoid arthritides in Finland [38].We found no
differences in HRQoL between different medication groups.
It is possible that smoking and overweight in the adult
population explain most of their inferior disease outcomes
compared to the JIA patients in this study. This highlights
the importance of encouraging especially young patients to
avoid smoking and to maintain a normal bodyweight in order
to sustain good treatment results throughout the lifecourse.
Engaging with and motivating young patients in the manage-
ment of their condition is vital for treatment success. Similarly,
Table 3 Associations of
individual variables and quality of







Variable rb P value β (SE) 95% CI P value
Age cohort, JIA vs. adults (adults as baseline) 0.330 < 0.001 0.071 − 0.010–0.036 0.278
Gender (female as baseline) 0.150 0.010 0.135 0.005–0.052 0.016
Smoking status (smoking as baseline) 0.285 < 0.001 0.245 0.032–0.088 < 0.001
Disease activity (active disease as baseline) 0.481 < 0.001 0.367 0.049–0.096 < 0.001
BMI, continuous − 0.200 0.001 − 0.151 − 0.005–0.000 0.016
Disease duration, continuous − 0.010 0.240 − 0.016 − 0.002–0.001 0.773
JIA juvenile idiopathic arthritis, BMI body mass index
aMann-Whitney U test for categorical variables and Spearman correlation for continuous variables
b For Mann-Whitney U tests, r was estimated using the formula r = z / square root of N
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a more holistic care and treatment approach including
smoking cessation programs and interventions for obesity
could benefit all RA patients attending follow-up in adult
clinics.
Funding The authors received no specific funding for this work.
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